Global Gavi, the world’s largest vaccine-focused public-private partnership has a new leader. Pakistani Senator Dr Sania Nishtar has officially assumed the role of CEO following a period of leadership uncertainty for the organisation and must now lay out Gavi’s strategic plan for 2026 to 2030, as well as convince its partners…
Denmark After transitioning from a fledgling biotech to a mature commercial-stage company on the back of its first approval, Zealand Pharma was hit with the challenges of commercialisation and the disappointing sales of its severe hypoglycemia treatment, Zegalogue. As a result, in 2022, the Danish firm did an about face, sacked…
Brazil Brazil’s ANVISA is commonly recognised as LatAm’s leading national medicines regulator and is defined by the Pan American Health Organization (PAHO) as a National Regulatory Authority of Regional Reference (NRAr) for medicines and vaccines. As part of our Transformative 2023: Regional Pharma Trends report, PharmaBoardroom’s Patrick Burton explores some of the key recent…
USA Nominated by President Joe Biden, the National Institutes of Health’s (NIH) new director Monica M. Bertagnolli took the reins of the world’s largest public funder of biomedical research earlier this month. With a clear focus on improving access and clinical trial diversity, Bertagnolli’s priorities for the role appear to align…
Europe Rainer Westermann, chairman of the Life Sciences Acceleration Alliance e.V. (LSAA), which lobbies on behalf of European venture capitalists in the life sciences space, launches a critique of current pharmaceutical policies across the EU, arguing that constant cost-containment measures, over-regulation, and bureaucracy are leading to drug shortages and acting as…
USA As debate rages over where to lay the blame for the USA’s drug affordability crisis, Katie Payne, senior vice president for strategic communications for the Pharmaceutical Care Management Association (PCMA) sets out a defence of the country’s pharmacy benefit manager (PBM) industry. Payne instead raises concerns with big drug companies’…
USA The pandemic revealed widespread pharmaceutical supply chain vulnerabilities in the United States, an issue the Biden administration has attempted to address partly through industry funding. The Chief Business Officer of Phlow, a company that has received federal government funding for manufacturing essential medicines in the US, spoke at the recent…
Europe The Swiss biotech sector again drew unprecedented levels of investment interest in 2021. Capital investments reached CHF 3.33B (USD 3.53B) in spite of the fact that R&D was focused mainly beyond COVID-19. According to the Swiss Biotech Report presented at the Swiss Biotech Day 2022 in Basel, the sector experienced…
InFocus HOMEPAGE Patient Engagement in the Era of CAR-T In recent years, the much-discussed concept of “patient centricity” has been top-of-mind across all corners of the pharma industry. This is especially pertinent now that many innovative drug makers are seeking to become much more than just purveyors of pills and expand…
Japan “This marks a significant moment in Takeda’s history and is an exciting step forward as we accelerate our transformation journey,” said Christophe Weber, Takeda’s CEO, after the USD 62 billion acquisition of international biotech Shire was completed in 2019. Two years later, the Japanese giant appears to finally be on…
HOMEPAGE Cannabis Five of the key emerging trends in the booming global medical cannabis and cannabinoid medicine industries… Read more WHITE PAPER Patents: A Key Factor in Winning the Cannabis Arms Race A new white paper from Fasken law firm asserts that the early filing of patents for innovative products is…
HOMEPAGE Rare Diseases Long regarded as a neglected backwater within the drug discovery landscape and the preserve of only a handful of niche players, the rare disease space has been undergoing an extraordinary turnaround in fortunes of late. According to EvaluatePharma’s forecasts, orphan drug sales are set to grow 11 percent each…
See our Cookie Privacy Policy Here